# Test Results: statistics/interpretation-brainstorming.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** statistics/interpretation-brainstorming.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I have completed an experiment and am interpreting the results. I want to think through possible interpretations thoroughly, including alternatives to my initial hypothesis.

Research question: {YOUR_RESEARCH_QUESTION}

Experimental design (brief): {KEY_DESIGN_FEATURES}

Results summary:
{DESCRIBE_YOUR_KEY_FINDINGS}
- Main finding: {PRIMARY_RESULT}
- Effect size: {MAGNITUDE_IF_AVAILABLE}
- Statistical outcome: {p-values, confidence intervals, etc.}
- Secondary findings: {OTHER_NOTABLE_RESULTS}
- Unexpected findings: {ANYTHING_SURPRISING}

My initial interpretation: {WHAT_YOU_THINK_IT_MEANS}

Task: Help me think through these results critically:

1. **Support for initial interpretation**: What evidence supports my interpretation? How strong is it?

2. **Alternative interpretations**: What other explanations could produce these results? For each alternative:
   - What would it predict?
   - How could I distinguish it from my interpretation?

3. **Potential confounds**: What factors might have influenced the results that aren't captured in my interpretation?

4. **Limitations to acknowledge**: What caveats should I include when presenting these findings?

5. **Questions for follow-up**: What additional experiments or analyses would strengthen the interpretation?

6. **What the results don't show**: What conclusions would be overreach?

Constraints:
- Be genuinely critical—I want to anticipate reviewer objections
- Don't just agree with my interpretation; actively generate alternatives
- Distinguish between plausible alternatives and unlikely ones
- Focus on scientific interpretation, not just statistical significance

Context: I have completed an experiment and am interpreting the results. I want to think through possible interpretations thoroughly.

Research question: Does fecal microbiota transplantation from lean donors improve metabolic outcomes in obese mice?

Experimental design (brief):
- 3 groups (n=10 each): Control (PBS), FMT from lean donors, FMT from obese donors
- High-fat diet-induced obese mice, 8 weeks treatment
- Measured: body weight, fasting glucose, microbiome composition

Results summary:
- Main finding: FMT-lean group had significantly lower fasting glucose than Control (p=0.01) and FMT-obese (p=0.03)
- Effect size: Mean glucose 145 vs 180 mg/dL (FMT-lean vs Control)
- Body weight: No significant differences between any groups
- Microbiome: FMT-lean group showed higher diversity and different community composition
- The donor-derived taxa were detectable in recipients
- Unexpected: FMT-obese group showed slightly (non-significant) lower glucose than Control

My initial interpretation: Lean-donor microbiota transfers metabolically beneficial effects to obese recipients, potentially through specific bacterial taxa that improve glucose regulation.
```

## Model Output
```


**Critical appraisal of the FMT experiment**

Below is a step‑by‑step walk‑through of how to interpret the data, what strengths the current evidence has, where alternative explanations could lurk, what confounds or limitations you should flag, and what follow‑up work would tighten the story.  I have tried to be genuinely skeptical—anticipating the kinds of objections a reviewer might raise—while still acknowledging what the data do support.

---

## 1. Support for the initial interpretation  

| Evidence | Why it backs the hypothesis | Strength of support |
|----------|----------------------------|---------------------|
| **FMT‑lean → lower fasting glucose** (p = 0.01 vs. Control; p = 0.03 vs. FMT‑obese) | Shows that receiving microbiota from a lean donor is associated with an improvement in a metabolic read‑out that is central to the research question. | Moderate‑to‑strong (statistically significant, effect size ≈ 35 mg/dL ≈ 20 % reduction). |
| **Microbiome shift** – higher α‑diversity and altered community composition in FMT‑lean recipients | Provides a mechanistic link: the transplant actually changed the gut ecosystem in the direction seen in lean donors. | Moderate (correlational; diversity alone does not prove causality). |
| **Detection of donor‑derived taxa** in recipients | Confirms that the transplant engrafted (at least transiently) and that the observed metabolic change co‑occurs with the presence of donor microbes. | Moderate (engraftment ≠ functional activity). |
| **No weight change** across groups | Suggests the glucose improvement is not simply a secondary effect of reduced adiposity; the effect is more specific to glucose homeostasis. | Helpful for isolating a glucose‑specific mechanism. |
| **FMT‑obese trend** (non‑significant lower glucose vs. Control) | Does not contradict the main finding; if anything, it hints that obese‑donor microbiota may be neutral or mildly beneficial, which is worth noting but does not weaken the lean‑donor effect. | Weak (non‑significant). |

**Overall:** The convergent evidence (metabolic phenotype + microbiome shift + donor taxa detection) gives a reasonably coherent story that lean‑donor FMT can improve glucose regulation in obese mice. However, the causal chain is still inferential; we have not directly shown *which* microbial functions are responsible.

---

## 2. Alternative interpretations  

Below are the most plausible alternatives, ordered roughly by plausibility given the data. For each I note (a) what it predicts, (b) how to test/distinguish it, and (c) a quick plausibility rating.

| # | Alternative explanation | What it predicts (beyond what you observed) | How to distinguish it from your interpretation | Plausibility* |
|---|--------------------------|--------------------------------------------|-----------------------------------------------|---------------|
| **A** | **Transient metabolic effect of the transplantation procedure itself** (e.g., stress, inflammation, or antibiotic‑like effects of the gavage) | Any FMT (lean or obese) would produce a short‑term glucose improvement that fades after a few days; the effect would be similar across donor types if the procedure is the driver. | • Measure glucose at multiple time points (e.g., 24 h, 3 d, 1 wk post‑gavage). <br>• Include a sham‑gavage control (PBS) that receives the same handling but no microbial material. <br>• If the lean‑FMT advantage persists beyond the acute window, the procedural effect is unlikely. | ★★★ (moderate) – many FMT papers report an early “engraftment stress” effect. |
| **B** | **Dietary or housing confounds** (e.g., subtle differences in food intake, coprophagy, or cage‑level microbiota transfer) | Mice receiving lean‑FMT might eat slightly less or have altered nutrient absorption, leading to lower glucose independent of specific taxa. Coprophagy could spread lean‑donor microbes to control cages, diluting differences. | • Monitor daily food intake and water consumption. <br>• House each treatment group in separate racks or use filter‑top cages to prevent cross‑contamination. <br>• Perform pair‑feeding experiments to equalize caloric intake. | ★★ (low‑moderate) – you already randomized groups, but cage effects can be subtle. |
| **C** | **Immune modulation unrelated to metabolism** (e.g., lean‑donor microbiota induces a tolerogenic immune state that indirectly improves glucose tolerance) | You would see changes in immune markers (e.g., reduced colonic IFN‑γ, increased Tregs, lower serum LPS‑binding protein) that correlate with glucose improvement, even if the microbes themselves are not directly metabolic. | • Profile cytokines, flow cytometry of gut lamina propria lymphocytes, or serum endotoxin levels. <br>• If immune shifts are present and correlate tightly with glucose, you could argue the mechanism is immunomodulatory rather than a direct microbial metabolite. | ★★★ (moderate) – immune‑metabolism crosstalk is well documented. |
| **D** | **Metabolite carry‑over in the inoculum** (e.g., short‑chain fatty acids, bile acids, or other metabolites present in the donor stool that are administered with the transplant) | The glucose benefit would be observed immediately after transplantation and would decay as the metabolites are cleared, regardless of whether the microbes engraft long‑term. | • Measure SCFA, bile acid, or other metabolite concentrations in the inoculum and in recipient plasma/feces at early (6 h) and later (1 wk) time points. <br>• Use a filtered inoculum (0.22 µm) that removes microbes but retains metabolites; if glucose improvement persists, metabolites are sufficient. | ★★ (low‑moderate) – plausible if you used fresh stool without metabolite quenching. |
| **E** | **Statistical fluctuation / multiple testing** (the observed p‑values are borderline and could be false positives) | Replication would yield a non‑significant or weaker effect; the effect size might shrink in a larger cohort. | • Increase n per group (e.g., to 20–30) and repeat the experiment. <br>• Apply a correction for multiple outcomes (weight, glucose, microbiome metrics). | ★ (low) – but always worth checking; the effect size is fairly large, making a pure fluke less likely. |
| **F** | **Donor‑specific non‑microbial factors** (e.g., differences in donor diet, medication, or genetic background that affect the stool composition beyond microbes) | The lean donor stool might contain higher levels of certain nutrients, fiber, or bioactive compounds that survive the transplant process and influence host metabolism. | • Characterize the donor stool metabolome (untargeted LC‑MS) and compare lean vs. obese donors. <br>• If distinct metabolites are present, test whether administering those metabolites alone recapitulates the glucose effect. | ★★ (low‑moderate) – donor phenotype can affect stool chemistry. |
| **G** | **Reverse causality: glucose improvement drives microbiome changes** (i.e., lower glucose alters gut environment, which then selects for a different microbiota) | The microbiome shift would be a *consequence* of improved glucose, not its cause. You would expect the microbiome changes to appear *after* the metabolic improvement. | • Sample feces at early time points (e.g., 24 h, 72 h) before glucose differences become evident; if microbiome shifts precede glucose changes, causality leans toward microbiota → metabolism. | ★★ (low‑moderate) – temporal ordering is key. |

\*Plausibility is a quick heuristic based on typical FMT literature and the specifics of your design (n = 10, 8‑week HFD, single‑time‑point read‑out).  

**Key take‑away:** The most credible challengers are (A) procedural/acute effects, (B) subtle housing/diet confounds, (C) immune mediation, and (D) metabolite carry‑over. Alternatives (E)–(G) are less likely but still worth ruling out with additional controls or temporal data.

---

## 3. Potential confounds not captured in your interpretation  

| Confound | How it could bias the result | Mitigation / check |
|----------|-----------------------------|--------------------|
| **Batch effects in donor stool preparation** (e.g., anaerobic vs. aerobic handling, storage time) | If lean donor stool was processed more carefully, it could retain more viable anaerobes, inflating the effect. | Standardize processing time, oxygen exposure, and storage temperature for all donors; record and report. |
| **Antibiotic or antimicrobial residues** in donor stool (e.g., from prior treatment) | Could suppress recipient microbiota unevenly, leading to apparent metabolic improvement unrelated to the intended taxa. | Screen donor stool for common antibiotics; consider using antibiotic‑free donors or washing steps. |
| **Circadian timing of measurements** | Glucose varies across the light‑dark cycle; if measurements were taken at different times for groups, apparent differences could be artefactual. | Randomize the time of day for glucose testing across groups, or always sample at the same circadian point. |
| **Stress from gavage** (especially if lean‑FMT mice received more handling due to perceived “success”) | Stress hormones (corticosterone) can acutely lower glucose. | Blind the operator to group assignment; use sham‑gavage controls. |
| **Microbiota contamination from the environment** (e.g., bedding, water) | Over the 8‑week period, environmental microbes could drift and obscure true donor effects, especially if one group’s cage microbiota inadvertently leans toward a lean‑type community. | Use individually ventilated cages (IVCs) or barrier housing; monitor cage microbiota periodically. |
| **Sex differences** (if not balanced) | Male and female mice respond differently to HFD and FMT; an imbalance could masquerade as a treatment effect. | Ensure equal sex distribution or analyze sex as a factor. |
| **Baseline microbiome variability** | Even with randomization, random drift could leave one group with a more “lean‑like” starting microbiome, amplifying the apparent effect of lean‑FMT. | Perform baseline 16S/rRNA sequencing and include baseline composition as a covariate in models. |

---

## 4. Limitations to acknowledge when presenting the findings  

1. **Sample size** – n = 10 per group provides modest power; while the effect size is large, replication with larger cohorts is needed to confirm robustness.  
2. **Single metabolic read‑out** – Only fasting glucose was reported; complementary metrics (e.g., insulin tolerance test, HOMA‑IR, oral glucose tolerance test) would strengthen the claim of improved glucose homeostasis.  
3. **Short‑term follow‑up** – Measurements were taken at the end of an 8‑week intervention; we do not know whether the effect persists, wanes, or requires continuous FMT.  
4. **Correlational microbiome data** – Diversity and taxon shifts are observational; functional validation (e.g., metagenomics, metabolomics, gnotobiotic validation) is lacking.  
5. **Potential for donor‑specific non‑microbial factors** – The stool preparation may have transferred metabolites, diet residues, or host‑derived molecules that could contribute to the phenotype.  
6. **Lack of mechanistic read‑outs** – No data on immune activation, gut barrier integrity, SCFA production, bile‑acid signaling, or hepatic lipid metabolism, which are plausible pathways linking microbiota to glucose.  
7. **Sex not specified** – If only one sex was used, generalizability to the opposite sex is uncertain.  
8. **Environmental contamination risk** – Standard mouse housing allows coprophagy and aerosol spread; without barrier controls, cross‑group microbial exchange could dilute or confound true differences.  

When you write the manuscript, list these points explicitly in a “Limitations” subsection; reviewers will appreciate the transparency.

---

## 5. Questions for follow‑up (experiments/analyses that would strengthen the interpretation)

| Goal | Suggested experiment / analysis | What it would clarify |
|------|--------------------------------|-----------------------|
| **Temporal ordering** | Serial fecal sampling (e.g., baseline, 3 d, 1 wk, 4 wk) + glucose testing at each point. | Determines whether microbiome shifts precede metabolic improvement. |
| **Dose‑response / durability** | Vary FMT frequency (single vs. weekly) and/or duration (4 wk, 8 wk, 12 wk). | Tests whether effect scales with exposure and whether it persists after cessation. |
| **Mechanistic mediators** | Measure SCFAs (acetate, propionate, butyrate), bile acids, gut permeability (FITC‑dextran), inflammatory cytokines (IL‑6, TNF‑α, IL‑10), hepatic gluconeogenesis genes (PEPCK, G6Pase). | Links specific microbial metabolites or immune changes to glucose outcome. |
| **Causality via metabolite transfer** | Prepare filtered (0.22 µm) donor stool supernatant; administer to obese mice. | If glucose improves, metabolites alone are sufficient; if not, live microbes are required. |
| **Immune mediation** | Deplete specific immune cells (e.g., anti‑CD25 for Tregs, clodronate liposomes for macrophages) in FMT‑lean mice; see if glucose benefit is lost. | Tests whether immune changes are necessary for the phenotype. |
| **Microbiota necessity** | Use antibiotics to eradicate recipient microbiota before FMT; compare engraftment and glucose outcomes. | Determines whether a “niche opening” is required for donor taxa to exert effects. |
| **Sex inclusion** | Repeat experiment in both males and females, analyze interaction. | Establishes whether the effect is sex‑dependent. |
| **Cross‑feeding / coprophagy control** | House mice in individually ventilated cages with filtered bedding; optionally use germ-free recipients colonized with defined communities. | Eliminates environmental microbial exchange as a confounder. |
| **Metabolomic profiling of donor stool** | Untargeted LC‑MS to identify differentially abundant metabolites between lean and obese donors; test candidate metabolites in vivo. | Pinpoints specific molecules that could mediate the effect. |
| **Statistical robustness** | Perform a priori power calculation; increase n to 15–20 per group; apply mixed‑effects models to account for cage effects. | Reduces risk of false positives and improves generalizability. |

---

## 6. What the results **do not show** (i.e., overreach to avoid)

| Overreach claim | Why it’s not justified by the current data |
|-----------------|--------------------------------------------|
| “Lean‑donor FMT **causes** long‑term improvement in glucose tolerance.” | Only a single fasting glucose measurement at one time point; no glucose tolerance test, insulin measurement, or longitudinal data. |
| “Specific bacterial taxa X, Y, Z are **responsible** for the metabolic benefit.” | Microbiome data show compositional shifts but no functional validation (e.g., gnotobiotic mono‑association, metabolite supplementation). |
| “The effect is **independent of weight change**.” | While weight did not differ significantly, the study was not powered to detect modest weight differences; a small but biologically relevant change in adiposity could still contribute. |
| “Obese‑donor FMT is **metabolically neutral or harmful**.” | The FMT‑obese group showed a non‑significant trend toward lower glucose; the study lacks power to draw any firm conclusion about obese donor effects. |
| “Findings translate directly to humans.” | Mouse HFD model, gavage‑delivered FMT, and short‑term read‑out limit translational relevance without further validation in human studies or humanized mouse models. |
| “The observed microbiome diversity increase **causes** the glucose improvement.” | Correlation ≠ causation; diversity could be a by‑product of altered gut environment secondary to improved glucose. |
| “The procedure is **safe** and has no off‑target effects.” | No assessment of liver histology, inflammation markers, or behavioral stress; safety claims require dedicated toxicology read‑outs. |

---

### Bottom line

Your data provide **reasonable, though not definitive**, evidence that transferring microbiota from lean donors can improve fasting glucose in obese, HFD‑fed mice. The strongest support comes from the concordant metabolic phenotype, microbiome shift, and detection of donor taxa. However, alternative explanations—particularly procedural effects, subtle housing/diet confounds, immune modulation, and metabolite carry‑over—remain plausible and should be addressed in follow‑up work. Acknowledging the sample size, lack of functional mechanistic data, and potential confounds will make your manuscript more robust and pre‑empt typical reviewer critiques. 

Feel free to let me know if you’d like a more detailed experimental plan for any of the follow‑up suggestions above!
```

## Overall Assessment
- **Recommendation:** Pass
- **Notes:**
## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
